Use of an inducible extracellular vesicle as a medicament for skin, health care products or skin care products. A composition, comprising the inducible vesicle and the medicaments or care products for skin.

The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.

The present invention relates to an extract of Silybum marianum (L.) Gaertn. akenes, as well as compositions containing this extract for application in the fields of cosmetics and dermatology for promoting hair growth.

The present invention relates to an extract of Silybum marianum (L.) Gaertn. akenes, as well as compositions containing this extract for application in the fields of cosmetics and dermatology for promoting hair growth.

Described herein are compositions for delaying onset or delaying progression of frailty, reversing aging phenotype, extending healthspan, compressing morbidity, increasing lifespan and reducing formation of senescent cells.

A use of acellular adipose tissue extract in promoting hair growth and retention. The acellular adipose tissue extract contains one or more components selected from the following: an insulin-like growth factor, a brain-derived neurotrophic factor, a glia-derived neurotrophic factor, a vascular endothelial growth factor, a liver growth factor, transforming growth factor β, a basic fibroblast growth factor, a platelet-derived growth factor, an epidermal growth factor, a granulocyte colony stimulating factor, or a combination thereof.

A use of acellular adipose tissue extract in promoting hair growth and retention. The acellular adipose tissue extract contains one or more components selected from the following: an insulin-like growth factor, a brain-derived neurotrophic factor, a glia-derived neurotrophic factor, a vascular endothelial growth factor, a liver growth factor, transforming growth factor β, a basic fibroblast growth factor, a platelet-derived growth factor, an epidermal growth factor, a granulocyte colony stimulating factor, or a combination thereof.

The present invention provides a process for the recovery and/or purification of a recombinantly expressed intracellular protein comprising the sequence of Annexin A5 (AnxA5) from an endotoxin-producing host cell with a cell wall, wherein the process comprises releasing the intracellular protein from the host cell, characterised in that the step of releasing the intracellular AnxA5 protein is conducted in the presence of a homogenisation buffer comprising non-ionic detergent, and preferably wherein the process does not include any centrifugation steps for the recovery and/or purification of the AnxA5 protein after its release from the host cell and/or in which the AnxA5 protein remains in solution throughout the process except when temporarily bound to any chromatographic resins.

A compound represented by general formula (I) wherein all the symbols are as defined in the specification has a selective S1P5 receptor agonist activity due to having a linker from a phenyl group to a cyclic substituent in a dihydronaphthalene skeleton; i.e., due to having a short linker of one atom or less as L in general formula (I), and can therefore serve as an agent for treating S1P5-mediated disease, e. g., neurodegenerative disease such as schizophrenia. ##STR00001##

The present invention relates to the use of CDK8 and/or CDK19 inhibitors in the treatment of ribosomopathies as well as conditions characterized by reduced number of hematopoietic stem cells and/or progenitor cells; and bone anabolic disorders.